SUBSCRIBE: Print / eNewsletter
FDA Approves Adjuvant Therapy for High-Risk Renal Cell Carcinoma
The FDA has approved a new indication for sunitinib (Sutent) to include the adjuvant treatment of renal cell carcinoma in patients at high risk of disease recurrence following nephrectomy.
Proton Therapy in Hodgkin Lymphoma Yields Favorable Acute Toxicity Profile
A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.